Table 2 Logistic regression model results for declining further specimen uses among captured SWOG trials 2000–2024.
Variable | Univariate odds ratio (95% confidence interval); p-value | Multivariable odds ratio (95% confidence interval); p-value |
|---|---|---|
Race (ref = White/Caucasian) | ||
Asian | 2.98 (1.94–4.56); <0.001 | 3.29 (2.04–5.30); <0.001 |
African American | 0.46 (0.27, 0.81); 0.006 | 0.5 (0.26–0.97); 0.041 |
Hawaiian/Pacific Islander | 5.44 (1.96–14.09); 0.001 | 10 (3.19–31.35); <0.001 |
Native American/Alaskan | 1.38 (0.47–4.11); 0.56 | 2.1 (0.67–6.62); 0.20 |
Ethnicity (ref = not Hispanic) | ||
Hispanic | 1.14 (0.77–1.69); 0.51 | 2.18 (1.4–3.4); <0.001 |
Disease status at treatment (ref = newly diagnosed) | ||
Relapsed/refractory disease | 0.43 (0.19–0.99); 0.047 | 0.76 (0.29–2.01); 0.58 |
Age in years at study registration | 1.03 (1.03–1.04); <0.001 | 1.03 (1.03–1.04); <0.001 |
Male gender (ref = female) | 0.98 (0.81–1.19); 0.83 | 0.86 (0.69–1.06); 0.15 |
Diagnosis (ref = AML) | ||
ALL | 0.76 (0.50–1.16); 0.20 | 3.82 (2.01–7.26); <0.001 |
CLL | 1.71 (1.01–2.90); 0.045 | 2.10 (1.07–4.12); 0.031 |
CML | 2.25 (1.74, 2.90); <0.001 | 3.13 (2.35–4.16); <0.001 |
APL | 0.28 (0.12–0.64); 0.0025 | 0.45 (0.19–1.04); 0.062 |
MDS | 3.34 (2.55.4.36); <0.001 | 2.92 (2.13–4.01); <0.001 |
Trial design (ref = randomized) | ||
Single-arm | 2.67 (1.98–3.61); <0.001 | 4.46 (2.85–6.97); <0.001 |
Clinical trial eligibility (ref = eligible) | ||
Not eligible | 1.02 (0.61, 1.73); 0.93 | 1.07 (0.62–1.86); 0.80 |
Registration study year (per year) | 1.00 (0.98–1.02); 0.83 | 0.96 (0.93–0.98); 0.0026 |
